CORRECTIONS







Correction to: Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial

An error appeared in the 15 August 2022 issue of the journal (Avery et al. "Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial." *Clin Infect Dis*; 75(4): 690–701. https://doi.org/10.1093/cid/ciab988). The "Discussion" section of the paper currently states: "A higher study discontinuation rate before week 8 in the IAT

group was also observed in the study. These discontinuations were primarily due to adverse events and toxicities known to be associated with available anti-CMV agents. Sensitivity analyses (Supplementary Table 2) were performed to address this potential bias." The reference in the previous sentence should be to Supplementary Table 3, not Supplementary Table 2.

The authors regret the error.

https://doi.org/10.1093/cid/ciac970

Correction to: Longitudinal Immune Response to 3 Doses of Messenger RNA Vaccine Against Coronavirus Disease (COVID-19) in Pediatric Patients Receiving Chemotherapy for Cancer

An error appeared in the corrected proof publication of this article (Lehrbecher et al. "Longitudinal Immune Response to 3 Doses of Messenger RNA Vaccine Against Coronavirus Disease (COVID-19) in Pediatric Patients Receiving Chemotherapy for Cancer." *Clin Infect Dis*; https://doi.org/10.1093/cid/ciac570). One of the authors, Judith Reemtsma, was inadvertently left off the author list. The full list of authors and their affiliations should read as follows:

Thomas Lehrnbecher, ^{1,a} Ulrich Sack, ^{2,a} Carsten Speckmann, ³ Andreas H. Groll, ⁴ Andreas Boldt, ² Benjamin Siebald, ¹ Simone

Clinical Infectious Diseases® 2023;76(3):560–2

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Hettmer,³ Eva-Maria Demmerath,³ Judith Reemtsma,² Barbara Schenk,⁵ Sandra Ciesek,^{5,6,7} Jan-Henning Klusmann,¹ Christian Jassoy,^{8,b} and Sebastian Hoehl^{5,b}

¹Division of Pediatric Hematology and Oncology, Hospital for Children and Adolescents, University Hospital, Johann Wolfgang Goethe University, Frankfurt am Main, Germany;

²Institute of Clinical Immunology, Medical Faculty, University of Leipzig, Leipzig, Germany;

³Division of Pediatric Hematology and Oncology, Department of Pediatric and Adolescent Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany;